Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corporation (NASDAQ: DXR) is a medical instrumentation and biotechnology company focused on blood volume measurement, and its news flow centers on developments in this specialized diagnostic area. The company describes itself as the global leader in blood volume measurement technology, with approximately 50 years of experience and a patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic platform.
News about Daxor frequently highlights regulatory milestones, such as FDA 510(k) clearance for its next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer (Daxor BVA™). Announcements also cover commercial expansion, including adoption of its BVA platform and ezBVA Lab Service by health systems, academic medical centers and cardiology practices, as well as deployments of on-site analyzers for immediate blood volume assessment.
Investors and clinicians following DXR can expect updates on clinical research that evaluates BVA-guided care in conditions like heart failure, LVAD implantation, cardiac amyloidosis, sepsis and COVID-19. Company releases summarize peer-reviewed studies and pilot trials that examine outcomes such as readmissions, survival, kidney injury and hospital length of stay when blood volume analysis is incorporated into care pathways.
Daxor’s news flow also includes participation in medical and investor conferences, where management presents corporate updates and showcases its technology to cardiovascular and critical care audiences, as well as institutional investors. For those tracking DXR, this news page offers a focused view of how the company’s blood volume analysis technology is progressing through regulatory clearance, clinical validation and market adoption over time.
Daxor (Nasdaq: DXR) will exhibit its Blood Volume Analyzer (BVA™) at the MedAxiom CV Transforum Spring’26, April 30–May 2, 2026, at Sawgrass Marriott, Ponte Vedra Beach, FL. The company says the forum supports its commercial strategy to engage cardiovascular decision-makers and accelerate BVA adoption to inform value-based care.
According to the company, peer-reviewed studies link BVA-guided care to large outcome differences: 30‑day mortality down 82%, 1‑year mortality down 86%, 30‑day readmissions down 56%, and 55% shorter length of stay when done on admission (P<0.001).
Daxor (Nasdaq: DXR) announced April 8, 2026 the launch of a new BVA program at a high-volume cardiology center in Southwest Ohio. The program uses Daxor’s Tennessee-based ezBVA Lab workflow to deliver 24-hour turnaround on blood volume analysis without onsite lab infrastructure.
This lab-as-a-service integration aims to enable data-driven heart failure care, leverage existing reimbursement codes, reduce capital barriers for providers, and speed clinical adoption across the region.
Daxor (Nasdaq: DXR) presented clinical data at SCCM 2026 showing its Blood Volume Analyzer (BVA) directly measures Albumin Escape Rate (AER) and detects capillary leak with higher mechanistic specificity than common clinical indices.
Key result: BVA identified a median 20% per hour albumin escape rate in patients while traditional scores remained uniformly low, suggesting clinical indices may miss significant vascular leak.
Daxor (Nasdaq: DXR) will exhibit at the American College of Cardiology Annual Scientific Session (ACC.26) in New Orleans, March 28–30, 2026, at Booth #1557. The company will showcase its new portable Blood Volume Analyzer (BVA), an FDA-cleared diagnostic that directly quantifies total blood, plasma, and red cell volume with >95% accuracy.
According to the company, peer-reviewed studies show BVA-guided care produced a 56% reduction in 30-day readmissions and an 82% reduction in 30-day mortality; Daxor highlights BVA as a tool to optimize fluid management and reduce the $3.5 billion annual Medicare heart-failure readmission burden.
Daxor (Nasdaq: DXR) will debut a new rapid, portable blood volume analyzer at the SCCM 2026 Critical Care Congress (Booth #906) in Chicago, March 22–24. The device aims to deliver rapid, lab-quality Blood Volume Analysis to ICUs and diverse clinical settings.
According to Daxor, peer-reviewed studies including a randomized controlled trial report BVA altered fluid and RBC interventions in 44% of cases and reduced mortality by 66% in surgical ICUs; the company positions the device to help address >5 million annual U.S. adult ICU admissions and >$100 billion in related healthcare spending.
Daxor (Nasdaq: DXR) announced that CEO and President Michael Feldschuh will participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026 on March 10–11, 2026.
Mr. Feldschuh will deliver a 30-minute presentation on March 10 at 2:00 PM ET and hold virtual one-on-one investor meetings on March 11. A live webcast is available at the conference webcast page and investors can request meetings via the conference website.
Daxor Corporation (Nasdaq: DXR) reported a transformative 2025 with FDA 510(k) clearance in August for a next‑generation portable Blood Volume Analyzer, unaudited operating revenue up 45% YoY, year‑end net assets of $45.89M ($9.07/share), and a post‑year $9.0M registered direct offering in January 2026.
The operating division narrowed losses to $268,598 in 2025 while investing in R&D, commercialization, and production to scale placements and sales.
Daxor (Nasdaq: DXR) reported fiscal 2025 results with operating revenue up 45% YoY and total net assets of $45,887,266 as of December 31, 2025. Net Asset Value per share rose to $9.07 (a $1.82 increase). The company received FDA 510(k) clearance in August 2025 for a next‑generation portable Blood Volume Analyzer and closed a $9.0 million registered direct offering in January 2026 at $11.75 per share to fund commercialization and expansion.
Daxor (Nasdaq: DXR) launched a BVA diagnostic program in Southern Middle Tennessee, expanding its outpatient cardiology presence on Feb. 24, 2026. The program uses the Tennessee-based ezBVA Lab to deliver comprehensive blood volume metrics with a 24-hour turnaround and claims 98% accuracy.
According to the company, the service integrates into outpatient workflows with existing reimbursement codes and requires zero capital investment for the facility.
Daxor (NASDAQ: DXR) announced it intends to change its primary reporting framework from the Investment Company Act to the Securities Exchange Act, reflecting its shift to an operating medical diagnostics business focused on Blood Volume Analysis (BVA). The company cited customer growth, revenue increases, and FDA clearance of its next-generation analyzer. Daxor expects to complete regulatory steps by the end of Q2, subject to required filings and approvals, and said Exchange Act reporting will provide standardized GAAP disclosures and improved investor comparability.